Compass Carter Osborne is pleased to share the second edition of our quarterly newsletter, focussing on all things Life Sciences.
Brought to you by CCO’s dedicated Life Sciences function, the team aim to share the latest industry news ranging from fundraising and deals, to research and clinical trial updates, as well as notable executive movements.
Overview of the second edition
In this first edition, the newsletter will outline the following:
- An overview and reflection by Principal Matt Dixon of the last quarter
- A selection of the most notable acquisitions, investments, partnerships and IPO news from Q2 of 2024
- Notable M&A events
Notable funding rounds
Clinical trial, research and drug approvals – A selection of the most notable clinical trials, R&D and drug approval news from Q2 of 2024
Executive Moves – A selection of people moves & insights from Q2 2024
To read the newsletter, download the full version here: Download
Find further information about Compass Carter Osborne news and events.
